Filing summary
Entity mismatch: The request identifies Microbot Medical Inc., but the supplied filing is StemCells, Inc.’s Form 10-K. This summary covers StemCells, Inc. and should not be attributed to Microbot Medical.
Business context and reporting period
The filing reports the fiscal year ended December 31, 2015, not a standalone fourth quarter. StemCells was a clinical-stage cell-therapy company developing purified human neural stem cells (HuCNS-SC), with its December 2015 strategy realignment prioritizing chronic spinal cord injury. The financial statements were audited; the auditor issued unqualified opinions on the financial statements and internal control over financial reporting.
Financial performance and liquidity
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue from continuing operations | $0.117 million | $1.012 million |
| Operating expenses | $36.837 million | $31.923 million |
| Operating loss | $36.720 million | $30.910 million |
| Net loss | $36.415 million | $32.741 million |
| Basic and diluted loss per share | $0.38 | $0.53 |
| Net cash used in operating activities | $30.679 million | $27.352 million |
| Cash and cash equivalents at year-end | $12.111 million | $24.988 million |
| Restricted cash at year-end | $2.423 million | None reported |
| Loan payable, net of discount | $10.334 million | $15.020 million |
| Stockholders’ equity (deficit) | $(0.334) million | $5.871 million |
The company had no meaningful product-sales base, and gross margin is not applicable to continuing operations as reported. Revenue was primarily licensing and grant income. Cash from financing activities was $18.707 million in 2015, including approximately $25 million of net proceeds from an April public offering and proceeds from at-the-market share sales. The company reported an accumulated deficit of approximately $456.7 million and said it expected further operating losses and needed additional capital; it warned that available resources might not fund operations beyond the next 12 months and that failure to raise funds could force program cuts or bankruptcy proceedings.
Material changes versus the prior comparable period
- Revenue fell 88% year over year, largely because 2014 included a roughly $500,000 licensing milestone and a roughly $400,000 Takara licensing fee associated with the SC Proven divestiture.
- Research and development expense rose 26% to $27.111 million, reflecting higher personnel, clinical-trial, supplies, and manufacturing-related facility costs. Total operating expenses rose 15%.
- Net loss increased from $32.741 million to $36.415 million; operating cash use increased by about $3.327 million.
- Unrestricted cash declined by 52%. Year-end debt included $1.417 million current and $8.917 million non-current; the filing describes the non-current amount as the CIRM loan balance whose forgiveness required legal release for accounting derecognition.
- Common shares outstanding increased from 68.7 million to 111.3 million during 2015. The company also reported 44.3 million warrants outstanding at year-end, in addition to options and restricted stock units.
Outlook, management commentary, and key risks
- In December 2015, management announced a realignment focused on chronic spinal cord injury. It suspended further enrollment in the Phase II Radiant dry-AMD study while seeking a partner for retinal development, and planned a workforce reduction of about 25% (17 employees), completed in January 2016. The company recorded a one-time $392,000 severance charge.
- Management estimated the realignment could reduce costs by approximately $20 million over two years, expedite completion of the ongoing Phase II Pathway spinal-cord-injury study, and enable commencement of a pivotal Phase III trial. These are plans, not assured outcomes.
- Pathway’s first six-patient cohort showed interim motor improvement in four patients at six months; the second cohort was enrolling. These early, small-cohort observations do not establish efficacy. The completed thoracic SCI study reported sensory gains in some patients, also preliminary findings.
- Principal risks include dependence on one early-stage cell platform, uncertain clinical and regulatory outcomes, substantial continuing cash needs, possible dilution or inability to raise capital, manufacturing and supply challenges, and intellectual-property risks. The filing also reports that certain patents were adjudged invalid in 2015, leading to dismissal of the company’s patent infringement case against Neuralstem.
- NASDAQ had granted an extension through May 9, 2016 to regain the $1 minimum bid-price requirement. At December 31, 2015, the share price was $0.42 and stockholders’ equity was negative, creating additional listing and financing risks.
- After year-end, in March 2016, the company reported an underwritten offering raising approximately $8 million gross. The offering included substantial warrant coverage and therefore potential dilution.
Investor verification priorities
- Confirm the issuer: the supplied filing is StemCells, Inc., not Microbot Medical Inc.; verify the intended company and filing before relying on these figures.
- Review the March 2016 financing’s net proceeds, warrant terms, and resulting fully diluted share count, and assess whether subsequent funding addressed the stated liquidity concerns.
- Verify current unrestricted cash, cash burn, debt repayment obligations, SVB covenant compliance, and the status and accounting treatment of the CIRM loan forgiveness.
- Check Pathway enrollment, controlled-cohort results, regulatory discussions, and whether the planned pivotal Phase III trial was initiated and funded.
- Confirm the progress of cost reductions, the status of the suspended Radiant study and any prospective development partner, and NASDAQ listing compliance.